To include your compound in the COVID-19 Resource Center, submit it here.

GrassMATAMPL: Phase II data

Top-line data from the double-blind, dose-ranging, U.S. Phase II G204 trial in about 265 patients

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE